Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Pharm Res ; 30(5): 1349-61, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23354770

RESUMO

PURPOSE: A rapid immune response is required to prevent death from Anthrax, caused by Bacillus anthracis. METHOD: We formulated a vaccine carrier comprised of acetalated dextran microparticles encapsulating recombinant protective antigen (rPA) and resiquimod (a toll-like receptor 7/8 agonist). RESULTS: We were able to protect against triplicate lethal challenge by vaccinating twice (Days 0, 7) and then aggressively challenging on Days 14, 21, 28. A significantly higher level of antibodies was generated by day 14 with the encapsulated group compared to the conventional rPA and alum group. Antibodies produced by the co-encapsulated group were only weakly-neutralizing in toxin neutralization; however, survival was not dependent on toxin neutralization, as all vaccine formulations survived all challenges except control groups. Post-mortem culture swabs taken from the hearts of vaccinated groups that did not produce significant neutralizing titers failed to grow B. anthracis. CONCLUSIONS: Results indicate that protective antibodies are not required for rapid protection; indeed, cytokine results indicate that T cell protection may play a role in protection from anthrax. We report the first instance of use of a particulate carrier to generate a rapid protective immunity against anthrax.


Assuntos
Vacinas contra Antraz/uso terapêutico , Antraz/prevenção & controle , Bacillus anthracis/imunologia , Dextranos/química , Portadores de Fármacos/química , Acetilação , Animais , Antraz/imunologia , Antraz/microbiologia , Vacinas contra Antraz/administração & dosagem , Vacinas contra Antraz/imunologia , Formação de Anticorpos , Antígenos de Bactérias/administração & dosagem , Antígenos de Bactérias/imunologia , Antígenos de Bactérias/uso terapêutico , Toxinas Bacterianas/administração & dosagem , Toxinas Bacterianas/imunologia , Toxinas Bacterianas/uso terapêutico , Imidazóis/administração & dosagem , Imidazóis/uso terapêutico , Camundongos , Receptores Toll-Like/agonistas , Vacinação , Vacinas de Subunidades Antigênicas/administração & dosagem , Vacinas de Subunidades Antigênicas/imunologia , Vacinas de Subunidades Antigênicas/uso terapêutico
2.
Mali Med ; 22(3): 1-4, 2007.
Artigo em Francês | MEDLINE | ID: mdl-19434985

RESUMO

The national policy of assumption of responsibility of the PVVIH decided to put 80% of new inclusions under Triomune, 1st therapeutic line made up of 3TC + D4T + Nevirapine. The use of Nevirapine among patients VIH+ plays a very important part in improvement of the quality of their life. The goal of this study was to evaluate the clinical and biological tolerance of Nevirapine at the PVVIH under treatment ARV and having Nevirapine in their diagram. We had collected 102 files of patients. The average age was 38 years. Association Lamivudine + Stavudine + Nevirapine was the diagram most frequently prescribed (82.4%). The skin, mucous and neurological signs, digestive disorders, muscular signs, cardiopulmonary signs were frequently observed in the first month of the treatment but these symptoms became less frequent in the third month and disappeared at the 6th month. We observed disorders in hepatic and renal functional parameters, rise in the lymphocytes. We obtained a considerable increase in the rate of CD4 between the beginning of the treatment and the 6th month. The treatment schema of 3TC + D4T + Nevirapine gives an excellent clinical and biological tolerance. But, the study must continue to confirm these results over a longer period.


Assuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Fármacos Anti-HIV/administração & dosagem , Nevirapina/administração & dosagem , Adulto , Quimioterapia Combinada , Feminino , Humanos , Lamivudina/administração & dosagem , Masculino , Pessoa de Meia-Idade , Estavudina/administração & dosagem , Resultado do Tratamento
3.
Mali Med ; 22(1): 18-21, 2007.
Artigo em Francês | MEDLINE | ID: mdl-19617117

RESUMO

OBJECTIVE: To study the factors associated with the observance of treatment ARV among patients followed in hospital medium to Bamako. METHOD: Inquire longitudinal with collection of the data near the patients followed in one of the three greater sites of assumption of responsibility of the people reached with the VIH/SIDA to Mali. The people were regarded as observing if they took at least 95% of their treatment the moment of the investigation. RESULTS: The patients were between 1 and 40 months of treatment the moment of the investigation. The average age was 44 years with extremes going from 19 to 70 years. Association Lamivudine +Stavudine + Nevirapine (triomune) was the most prescribed antiretroviral therapy (34.2%). The bad observance was noted at 58.5% of the patients. The principal causes of bad observance were: the lapse of memory 47.5% (96/202) and difficulties of access to the hospital 34.6% (70/202). The changes of molecules were due primarily to the out-of-stock condition, and the side effects. The factor associated with a good observance was the assistance of the patient by a member of the family informed of seropositivity. CONCLUSION: The interest of HIV patient to his treatment could contribute to enhance antiretroviral Adherence particularly in this hospital and generally in Mali.


Assuntos
Antirretrovirais/uso terapêutico , Infecções por HIV/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Adulto , Idoso , Hospitais , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...